Treatment for Autism Spectrum Disorder using TB006

A Multi-center Double Blind Placebo Controlled Study to Assess the Safety and Efficacy of TB006 for Improving Core Symptoms in Adults With Autism Spectrum Disorder

This study is testing a new treatment called TB006 to see if it can help adults with Autism Spectrum Disorder feel better by improving their symptoms.

Quick facts

• Phase: PHASE2
• Study type: Interventional
• Enrollment: 45 (estimated)
• Ages: 18 Years to 35 Years
• Sex: All
• Sponsor: Rossignol Medical Center (other)
• Locations: 2 sites (Phoenix, Arizona and 1 other locations)
• Trial ID: NCT06500637 on ClinicalTrials.gov

What this trial studies

This clinical trial is a multisite, 14-week, double-blind, placebo-controlled study designed to evaluate the efficacy of TB006, a monoclonal antibody targeting Galectin-3, in adults with Autism Spectrum Disorder (ASD). Participants will be randomly assigned to receive either TB006 or a placebo in a 2:1 ratio, followed by a 14-week open-label extension for those initially receiving placebo. The study aims to assess improvements in core and associated behavioral symptoms of ASD while monitoring safety and tolerability. The trial will include a comprehensive evaluation of participants' ongoing treatments to ensure consistency throughout the study period.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 to 35 with a diagnosis of Autism Spectrum Disorder and moderate to severe symptoms.

Not a fit: Patients with specific genetic markers related to Galectin-3 or a history of adverse reactions to immunoglobulin products may not benefit from this treatment.

Why it matters

Potential benefit: If successful, this treatment could significantly improve behavioral symptoms in adults with Autism Spectrum Disorder.

How similar studies have performed: While the approach of targeting neuroinflammation in ASD is promising, this specific treatment with TB006 is novel and has not been extensively tested in prior studies.

Eligibility criteria

Inclusion Criteria:

1. Autism Spectrum Disorder as defined below by the ADOS or ADI-R.
2. Between 18 and 35 years of age at baseline.
3. English included in the languages in which the individual is being raised.
4. Autism severity of moderate or higher (≥4) under the 7-item clinical global impression-severity scale.
5. Ability to maintain all ongoing complementary, dietary, traditional, and behavioral treatments constant for the study period.
6. Unchanged complementary, dietary, traditional, and behavioral treatments for two months prior to study entry.
7. In males and females of childbearing age, two forms of birth control must be used unless they are not sexually active.
8. A caretaker who will accompany the patient to all procedures and has adequate contact with the participant to complete caregiver questionnaires.

Exclusion Criteria:

1. LGALS3 rs4644 single nucleotide polymorphism with two copies of the Variant-type allele.
2. History of infusion reactions to immunoglobulin product.
3. Significant self-abusive or violent behavior or evidence of suicidal ideation, plan or behavior.
4. Severely affected as defined by CGI-Severity Standard Score = 7 (Extremely Ill).
5. Severe prematurity (\<34 weeks gestation) as determined by medical history.
6. Current uncontrolled gastroesophageal disorders.
7. Current or history of liver or kidney disease as determined by medical history and safety labs (See Laboratory Values Monitoring Plan for specific laboratory values).
8. Genetic syndromes.
9. Congenital brain malformations.
10. Active Epilepsy Diagnosis (Epilepsy Diagnosis is defined as History of two or more unprovoked seizures; Patient with a history of epilepsy who have been off medication without seizures for more than two years do not qualify as active epilepsy).
11. Any medical condition that the PI determines could jeopardize the safety of the study subject or compromise the integrity of the data.
12. Significant negative reaction (i.e., fainting, vomiting, etc.) because of a previous blood draw.
13. Failure to thrive or \< 5%ile for Body Mass Index or weight at the time of screening.
14. Concurrent treatment with drug that would significantly interact with the investigational product.
15. Allergy or Sensitivity to ingredients in the investigational product or placebo.
16. Evaluation with the NIH Toolbox or BOSCC within 3 months of entering the study.
17. Planned evaluation with the NIH Toolbox or BOSCC during the study.
18. Pregnancy
19. Current DSM-5 diagnosis requiring alternative pharmacotherapy, e.g., Major Depression, Bipolar Disorder, a psychotic disorder (based on clinical assessment assisted by the Child and Adolescent Symptom Inventory).
20. Refusal to comply with the use of birth control if sexually active.
21. Abnormal vital signs (systolic blood pressure \> 180 mmHg or \< 90 mmHg; heart rate \> 120 beats per minute or \< 55 beats per minute; temperature \> 101.0o F; oxygen saturation \< 90%)
22. Prolonged QTc (defined as \> 450ms for males and \>470ms for female) or any abnormalities felt by the investigator to be of concern.

Where this trial is running

Phoenix, Arizona and 1 other locations

• Rossignol Medical Center — Phoenix, Arizona, United States (RECRUITING)
• Rossignol Medical Center — Aliso Viejo, California, United States (RECRUITING)

Study contacts

• Principal investigator: Daniel A Rossignol, MD — Rossignol Medical Center
• Study coordinator: Alina Espinoza

Conditions: Autism Spectrum Disorder